The biotech drug developer posted revenue of $41.2 million in the period. The company's shares closed at $3.49. A year ago, they were trading at ...
News
- Minerva Neurosciences: 2Q Earnings Snapshot
- PET TALK: 'Bee' aware of insect stings this summer
... a clinical assistant professor and emergency and critical care specialist at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, ...
- Two Texas companies among initial public offerings scheduled to debut this week
Business: Phase 2 biotech developing therapies for neurodevelopmental disorders. Rackspace Technology – San Antonio, Texas, 33.5 million shares ...
- Does a plastic face shield protect you and others as well as a mask?
But the author of the study, William Lindsley, a research biomedical engineer at the National Institute for Occupational Safety and Health, told NBC ...
- The Latest on the Coronavirus Vaccine
... is being co-developed by researchers at NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the biotech company Moderna, Inc.